New hope for rare vasculitis: Three-Drug trial targets Non-Responders
NCT ID NCT04871191
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial is for people with granulomatosis with polyangiitis (GPA), a rare autoimmune disease causing blood vessel inflammation, who did not get better with standard treatments. It compares three salvage therapies: rituximab plus another drug, tocilizumab, or tofacitinib. The goal is to see which best induces remission over 52 weeks in 42 participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- rituximab, tocilizumab, or tofacitinib
- What this could lead to
- If successful, this trial could identify a more effective treatment option for people with granulomatosis with polyangiitis who do not respond to standard therapy, potentially improving remission rates.
- What could go wrong
- This is a small, early-phase trial with only 42 participants, so results may not apply to everyone. The treatments have known side effects, and it is uncertain if any will prove significantly better than current options.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hôpital de la Croix Saint Simon
RECRUITINGParis, 75020, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Promising vasculitis drug trial halted early
- Experimental liquid drug tested in ventilator patients with rare lung bleeding disease
- Could a single infusion of supercharged immune cells tame incurable autoimmune diseases?
- New hope for Wegener's patients: drug aims to stop flare-ups
- Steroid showdown: can a tiny daily dose keep a rare disease at bay?
- New cell therapy hopes to tame tough autoimmune diseases